2nd Quarter - Report

ACADIA PHARMACEUTICALS for ACADIA PHARMACEUTICALS

Period 2nd Quarter 2024 Filed Jul 22, 2024 Signed by Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals

Official filing
Firm
ACADIA PHARMACEUTICALS
Client
ACADIA PHARMACEUTICALS
Income
—
Expenses
$450,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Implementation of the Inflation Reduction Act of 2022; Help Copays Act (HR 830 / S 1375); Orphan Cures Act (HR 5539 / S 3131); National Plan to End Parkinson's Act (HR 2365 / S 1064); Protect Rare Act (HR 6094); The Creating Hope Reauthorization Act (HR 7384 / S 4583); Protecting and Preserving Social Security Act (S 4583).

LobbyistCovered position, as disclosed
MICHAEL MATTOON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 830 (118th), H.R. 2365 (118th), H.R. 6094 (118th), H.R. 7384 (118th), H.R. 5539 (118th)

Medicare/Medicaid MMM

Implementation of the Inflation Reduction Act of 2022; Issues related to protecting patient access to medicines in Medicare; Issues related to access to medicines for Parkinson's disease patients; Issues Related to Antipsychotic use in Medicaid (HR 4096); Orphan Cures Act (HR 5539 / S 3131); National Plan to End Parkinson's Act (HR 2365 / S 1064); Protect Rare Act (HR 6094); EPIC Act (HR 7174).

LobbyistCovered position, as disclosed
MICHAEL MATTOON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4096 (118th), H.R. 6094 (118th), H.R. 5539 (118th), H.R. 7174 (118th), H.R. 2365 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.